Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Among CU participants, men had lower Aβ42 and GFAP, and higher p-tau217/Aβ42. Among the CI group, GFAP, p-tau217 and p-tau217/Aβ42 were higher in women. Overall classification performance was similar across sexes; however, p-tau217 and p-tau217/Aβ42 showed higher specificity and positive predictive value in CU women, with the opposite pattern observed in CI participants. In CU participants, p-tau217 and p-tau217/Aβ42 predicted modified Preclinical Alzheimer Cognitive Composite decline only in women. Sex-specific plasma biomarker cutoffs may not be necessary. However, sex influences biomarker levels, classification metrics, and prognostic value, highlighting the importance of considering sex differences when interpreting biomarker results and optimizing trial enrichment strategies.

What this study adds

Evidence grade: Low

Sex influenced plasma biomarker levels, classification metrics and prognostic value, though overall classification performance was similar across sexes. This is about interpreting biomarkers and enriching trials, not about treating or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Milà‐Alomà, M., Hausle, I., Myoraku, A., Sorensen, C., Thropp, P., Shaw, L. M., et al. (2026). Sex differences in Alzheimer's disease plasma biomarker levels and clinical utility. Alzheimer s & Dementia. https://doi.org/10.1002/alz.71244

Vancouver

Milà‐Alomà M, Hausle I, Myoraku A, Sorensen C, Thropp P, Shaw LM, et al. Sex differences in Alzheimer's disease plasma biomarker levels and clinical utility. Alzheimer s & Dementia. 2026. doi:10.1002/alz.71244. PMID: 41755682.

BibTeX

@article{milaaloma2026-41755682,
  author  = {Milà‐Alomà, Marta and Hausle, Isabella and Myoraku, Alison and Sorensen, Clara and Thropp, Pamela and Shaw, Leslie M. and Weiner, Michael Walter and Tosun, Duygu and others},
  title   = {{Sex differences in Alzheimer's disease plasma biomarker levels and clinical utility}},
  journal = {Alzheimer s \& Dementia},
  year    = {2026},
  doi     = {10.1002/alz.71244},
  pmid    = {41755682},
  url     = {https://doi.org/10.1002/alz.71244}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Sex influenced plasma biomarker levels, classification metrics and prognostic value, though overall classification performance was similar across sexes. This is about interpreting biomarkers and enriching trials, not about treating or preventing Alzheimer's disease.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 9.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author for the Alzheimer’s Disease Neuroimaging Initiative: h-index 12 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, Berkeley: institution h-index 2,012 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41755682)
Free to read 2 / 2 Free to read
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →